Cybrexa Therapeutics Closes $25 Million Series B Financing

NEXT STORY
Ascendis Pharma A/S Announces Seven Presentations at ENDO 2021, Demonstrating Commitment to People with Rare Endocrine Diseases
PREV STORY
In-vitro Diagnostics (IVD) Market to Reach $118.5 Billion by 2027, Growing at a CAGR of 7% from 2020 with the Increasing Demand for Infectious Disease Testing – Meticulous Research® Analysis
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Adial Pharmaceuticals Appoints Two Additional Global Thought Leaders to its Scientific Advisory Board to Advance AD04 and Combat Alcohol Use Disorder

CHARLOTTESVILLE, Va., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a ...

author_avatar
NASDAQ Market News

In-Vitro Diagnostics (IVD) Market Slated to Bring in USD 102,554.24 million by End of 2023 | POC Testing to Expedite In-vitro Diagnostics Industry Demand, Says MRFR

author_avatar
NASDAQ Market News

Harpoon Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

author_avatar
NASDAQ Market News